Capstone Investment Advisors LLC Acquires 12,575 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Capstone Investment Advisors LLC increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 32.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,454 shares of the company’s stock after acquiring an additional 12,575 shares during the quarter. Capstone Investment Advisors LLC’s holdings in Privia Health Group were worth $1,008,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of PRVA. Park Place Capital Corp increased its stake in Privia Health Group by 115.4% in the first quarter. Park Place Capital Corp now owns 2,492 shares of the company’s stock valued at $49,000 after purchasing an additional 1,335 shares in the last quarter. Benjamin Edwards Inc. increased its position in Privia Health Group by 44.9% in the 4th quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock valued at $75,000 after buying an additional 1,003 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in Privia Health Group during the 4th quarter worth approximately $158,000. International Assets Investment Management LLC boosted its holdings in Privia Health Group by 2,721.7% in the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock worth $164,000 after acquiring an additional 6,886 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Privia Health Group by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock worth $176,000 after acquiring an additional 756 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Activity

In other Privia Health Group news, EVP Thomas Bartrum sold 2,252 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $41,481.84. Following the completion of the transaction, the executive vice president now owns 103,862 shares in the company, valued at $1,913,138.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Adam Boehler purchased 5,306 shares of Privia Health Group stock in a transaction dated Wednesday, May 29th. The stock was bought at an average cost of $16.50 per share, for a total transaction of $87,549.00. Following the completion of the transaction, the director now owns 5,773,158 shares in the company, valued at $95,257,107. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas Bartrum sold 2,252 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total value of $41,481.84. Following the sale, the executive vice president now directly owns 103,862 shares in the company, valued at approximately $1,913,138.04. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 293,235 shares of company stock valued at $4,745,481 and have sold 45,457 shares valued at $827,810. Insiders own 14.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PRVA. Citigroup started coverage on shares of Privia Health Group in a research report on Monday, April 22nd. They issued a “buy” rating and a $25.00 price target for the company. Stifel Nicolaus reduced their price objective on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Barclays lowered their target price on shares of Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating on the stock in a report on Monday, May 20th. Baird R W upgraded Privia Health Group to a “strong-buy” rating in a research note on Thursday, May 30th. Finally, Truist Financial decreased their price objective on Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.92.

Privia Health Group Stock Up 0.8 %

NASDAQ PRVA traded up $0.13 during trading hours on Friday, reaching $17.08. 401,234 shares of the company were exchanged, compared to its average volume of 679,954. The stock has a market capitalization of $2.04 billion, a P/E ratio of 113.87, a P/E/G ratio of 2.66 and a beta of 0.78. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $28.23. The business’s 50 day simple moving average is $17.38 and its 200-day simple moving average is $19.60.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $415.24 million for the quarter, compared to analysts’ expectations of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. As a group, sell-side analysts anticipate that Privia Health Group, Inc. will post 0.2 earnings per share for the current year.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.